Manufacturing & Off-the-shelf Scalability
Current autologous cell therapies that are generated from a patient’s own cells require weeks to prepare. Unlike most T cells, natural killer cells can be given off-the-shelf, meaning that they do not need to be tailored to an individual patient which allows for a streamlined manufacturing process and increased scalability. Moreover, oNK cells can be cryopreserved so that they are ready when patients need them. Cumulatively, these benefits translate to lower costs and greater availability for patients.